A Phase 2 interventional study of Exemestane and Tamoxifen in Breast Cancer, Ductal Carcinoma and Estrogen-receptor-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Prevention
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.
Among the 103 studies testing exemestane in Breast Neoplasms, this one is the 47th largest by planned enrollment of the 101 interventional ones that give a count, is one of 4 that started in 2026, is one of 50 in phase 2, reaches primary completion later than 10 of the 25 other live ones, and was the 102nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
Andrea DeCensi · Sites in Italy
Women only
Peking University People's Hospital · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, exemestane is the treatment under test here. Read study by study →
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 52 · Phase 3 36 · Phase 4 7
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 123 across the 101 interventional studies. Of the 60 that completed or were terminated, 27 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 103 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
142 studies in Breast Neoplasms by Dana-Farber Cancer Institute: 15 open now, 43 under way, none of them phase 3. Of 95 finished, 45 (47%) have results posted.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 26th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2026, is one of 56 in phase 2, reaches primary completion later than 25 of the 42 other live ones, and was the 138th registered.
Dana-Farber Cancer Institute’s Breast Neoplasms studies by the year they started, since 1998.
4 of the studies testing exemestane in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT06364267Andrea DeCensiLow Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. | 2027-01-31 |
| NCT07499999Dana-Farber Cancer InstituteRandomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer | 2027-08-31 |
| NCT07299890Anhui Provincial Cancer HospitalAn Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 103 studies testing exemestane in Breast Neoplasms, from their registry updates:
Among Dana-Farber Cancer Institute’s 142 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
The names of the study drugs involved in this study are:
This randomized, double-blind, phase II trial is to evaluate the efficacy and safety of low-dose "baby" exemestane versus low-dose "baby" tamoxifen in post-menopausal women at high risk for breast cancer. Both medications are used at full doses for breast cancer treatment and to reduce breast cancer risk. Low dose tamoxifen has been shown to be effective at reducing risk with better tolerance.
Participants will be randomized into one of two study groups: Group A: Exemestane versus Group B: Tamoxifen. Randomization means a participant is placed into a study group by chance. Neither a participant or the research doctor will choose or know what group a participant is placed in. This is called a "double-blind".
The U.S. Food and Drug Administration (FDA) has not approved tamoxifen or exemestane for ER+ DCIS, High Risk Lesions, or being at high-risk for breast cancer but it has been approved for other uses.
The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, Mammography scans, and bone density (DEXA) scans.
Participation in this research study is expected to last about 12 months. It is expected that about 140 people will take part in this research study. The Breast Cancer Research Foundation is supporting this research study by providing funding. MRIGlobal is providing support by supplying the study drugs.
Inclusion Criteria:
Any of the following criteria must be met:
ᶥ While DCIS and ADH are routinely excised, and treatment of DCIS often includes radiotherapy, lobular neoplasia (ALH and classic LCIS) are not routinely excised in most US centers unless radiologic-pathologic findings are discordant given the very low risk of an associated cancer.11,12 Participants with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy. All DCIS will require excision to clear margins per the SSO/ASCO/ASTRO margin guidelines for DCIS.88 In selected cases, the decision to omit RT might be taken according to low risk clinical-pathological factors (e.g., age>70, low grade, size \< 1 cm, and genomic assays if available) as well as patient preference after full discussion of the risks and benefits.
Exclusion Criteria:
Screening Eligibility Criteria
To register a participant to the screening phase, the following documents should be provided by the participating site:
Signed participant consent form
Postmenopausal status, and any of the following:
Only women will be recruited in the study given that breast cancer is much more frequent in women than men and because exemestane is in men because of risk of uncontrolled gonadal stimulation. Women of all races and ethnic groups are eligible for this trial. At participating sites, efforts will be made to enroll women from diverse ethnic and socio-economic backgrounds, including recruitment of non-white women in a selected New York city area.
NIH policy requires that women and members of minority groups and their subpopulations be included in all NIH-supported biomedical and behavioral research projects involving NIH-defined clinical research unless a clear and compelling rationale and justification establishes to the satisfaction of the funding Institute \& Center (IC) Director that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. Exclusion under other circumstances designated by the Director, NIH, upon the recommendation of an IC Director based on a compelling rationale and justification. Cost is not an acceptable reason for exclusion except when the study would duplicate data from other sources. Women of should not be routinely excluded from participation in clinical research.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized 1:1 with a permuted-block technique and stratified by center and will complete: * Baseline visit with assessments * Predetermined dose of Exemestane 1x on every odd day for 12 months * 3 month in-clinic visit * 6 month in-clinic visit * 9 month in-clinic visit * 12 month end of intervention in-clinic visit * Follow up for 12 months
Drug: Exemestane
Participants will be randomized 1:1 with a permuted-block technique and stratified by center and will complete: * Baseline visit with assessments * Predetermined dose of Tamoxifen 1x on every odd day for 12 months * 3 month in-clinic visit * 6 month in-clinic visit * 9 month in-clinic visit * 12 month end of intervention in-clinic visit * Follow up for 12 months
Drug: Tamoxifen
A steroidal aromatase inhibitor, blinded capsules taken orally, per protocol.
Also known as: C20H24O2
A selective estrogen receptor modulator, blinded capsules taken orally, per protocol.
Also known as: C32H37NO8
Difference in Overall Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) Between the Two Arms at 12 Months
The MENQOL assesses the degree to which menopausal symptoms are troublesome in four domains: vasomotor (three items), sexual (three items), physical (seven items), and psychosocial (16 items). Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 to 6, where 0 indicates "not at all bothered" and 6 indicates "extremely bothered." For each participant, the difference between the baseline and 12-month overall MENQOL score will be calculated and defined as the "change."
Time frame: 12 Months
Difference of Free Estradiol Levels between Two Arms at 12 Months
Free estradiol concentration in blood will be measured to compare the hormonal effects of babyexe versus babytam.
Time frame: 12 Months
Difference of Estradiol/Sex Hormone Binding Globulin (SHBG) Levels between Two Arms at 12 Months
The estradiol/SHBG ratio will be calculated as total estradiol divided by SHBG to evaluate differences in hormonal effects between babyexe and babytam.
Time frame: 12 Months
Difference of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Levels Between Two Arms at 12 Months
Blood levels of IGF-I will be measured to compare the effects of babyexe and babytam on IGF-I.
Time frame: 12 Months
Insulin-like Growth Factor I (IGF-I)/Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Ratio Between Two Arms at 12 Months
The ratio of IGF-I to IGFBP-3 in blood will be calculated to compare the effects of babyexe and babytam on IGF system balance.
Time frame: 12 Months
Overall Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) at 6 Months
The MENQOL assesses the degree to which menopausal symptoms are troublesome in four domains: vasomotor (three items), sexual (three items), physical (seven items), and psychosocial (16 items). Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 to 6, where 0 indicates "not at all bothered" and 6 indicates "extremely bothered." For each participant, the difference between the baseline and 6-month overall MENQOL score will be calculated and defined as the "change."
Time frame: 6 months
Free Estradiol Levels
Free estradiol concentration in blood will be measured to compare the hormonal effects of babyexe versus babytam.
Time frame: 6 Months
Estradiol/Sex Hormone Binding Globulin (SHBG) Levels
The estradiol/SHBG ratio will be calculated as total estradiol divided by SHBG to evaluate differences in hormonal effects between babyexe and babytam.
Time frame: 6 months
Insulin-like Growth Factor I (IGF-I) Levels
Blood levels of IGF-I will be measured to compare the effects of babyexe and babytam on IGF-I.
Time frame: 6 months
Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Levels
Blood levels of IGFBP-3 will be measured to compare the effects of babyexe and babytam on IGFBP-3.
Time frame: 6 months
Insulin-like Growth Factor I (IGF-I)/Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Ratio
The ratio of IGF-I to IGFBP-3 in blood will be calculated to compare the effects of babyexe and babytam on IGF system balance.
Time frame: 6 months
Physical Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) Between the Two Arms at 6 Months and 12 months
The MENQOL physical domain, which includes seven items, assesses the degree to which physical menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month physical domain MENQOL score will be calculated and defined as the "change."
Time frame: 6 months and 12 months
Sexual Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)
The MENQOL sexual domain, which includes three items, assesses the degree to which sexual menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month sexual domain MENQOL score will be calculated and defined as the "change."
Time frame: 6 months and 12 months
Psychosocial Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)
The MENQOL psychosocial domain, which includes sixteen items, assesses the degree to which psychosocial menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month psychosocial domain MENQOL score will be calculated and defined as the "change."
Time frame: 6 months and 12 months
Vasomotor Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL)
The MENQOL vasomotor domain, which includes three items, assesses the degree to which vasomotor menopausal symptoms are troublesome. Each item is answered with Yes or No. If the response is Yes, the participant rates how bothersome the symptom was on a scale from 0 ("not at all bothered") to 6 ("extremely bothered"). For each participant, the difference between the baseline and 6-month vasomotor domain MENQOL score will be calculated and defined as the "change."
Time frame: 6 months and 12 months
Global Adverse Event (AE) Rate
Global AE rate is defined as the proportion of participants who experience any AE. AE is summarized and graded based on CTCAE v 5.0.
Time frame: 12 Months
Grade 2 or Higher Adverse Event (AE) Rate
Grade 2 or higher AE rate is defined as the proportion of participants who experience grade 2 or higher AE. AE is summarized and graded based on CTCAE v 5.0.
Time frame: 12 months
Grade 3 or Higher Adverse Event (AE) Rate
Grade 3 or higher AE rate is defined as the proportion of participants who experience grade 2 or higher AE. AE is summarized and graded based on CTCAE v 5.0.
Time frame: 12 months
Distribution of Maximum Adverse Event Grade per Participant
The maximum adverse event (AE) grade experienced by each participant during the treatment period will be summarized to characterize the overall toxicity profile. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. For each participant, the highest AE grade observed at any time during the treatment period will be identified, and the distribution of these maximum grades across participants will be reported, in accordance with the statistical considerations for toxicity evaluation described in Section 16.15 of the protocol.
Time frame: 12 months
Medication Adherence Assessed by PMAS
Medication adherence will be assessed using the PMAS instrument, as specified in Appendix H of the protocol. PMAS is a validated wording-based adherence scale and does not generate a continuous numeric summary score. Therefore, adherence will be operationalized categorically, consistent with its original validation methodology. Participants will be classified into predefined adherence categories based on their item responses (e.g., high adherence versus non-high adherence). Adherence will be summarized as the proportion of participants meeting the definition of "high adherence" within each treatment arm. Between-arm comparisons will be based on categorical distributions rather than mean or continuous scores, in accordance with Sections 9.10-9.11 of the protocol.
Time frame: 6 months and 12 months
BPI (Brief Pain Inventory) Score Change from Baseline
Pain will be assessed using BPI, a validated questionnaire that measures both pain intensity and the degree to which pain interferes with daily activities. Each item is scored from 0 to 10, with higher scores indicating worse pain or greater interference.
Time frame: 6 months and 12 months
C-Telopeptide Levels
Blood levels of C-telopeptide, a marker of bone resorption, will be measured assess changes in bone turnover.
Time frame: 6 months and 12 months
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: DFCI- Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 11 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Exemestane · Tamoxifen
Dana-Farber Cancer Institute →